G1 Therapeutics reports Q2 EPS 14c, consensus (22c)

Reports Q2 revenue $42.4M, consensus $28.9M. “We know the impact that trilaciclib can have on the lives of people battling cancer; we see it every day in patients with extensive stage small cell lung cancer who receive COSELA prior to their chemotherapy. And, we’ve made good progress in further developing the potential of the drug in clinical trials for additional indications,” said Jack Bailey, CEO of G1 Therapeutics. “As such, our focus remains on driving depth of COSELA usage and adoption in our top accounts, despite a national platinum-based chemotherapy shortage. We are also preparing for multiple important data readouts expected early next year, and ensuring our continued financial strength.”